Global Cytomegalovirus Treatment (CMV) Market Size Study & Forecast, by Application (Stem Cell Transplantation, Organ Transplantation, Congenital CMV Infection, Other Applications), by Distribution Channel (Hospital pharmacies, Retail Pharmacies, E-commer

Global Cytomegalovirus Treatment (CMV) Market Size Study & Forecast, by Application (Stem Cell Transplantation, Organ Transplantation, Congenital CMV Infection, Other Applications), by Distribution Channel (Hospital pharmacies, Retail Pharmacies, E-commerce), and Regional Analysis, 2023-2030

Global Cytomegalovirus Treatment (CMV) Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.10% during the forecast period 2023-2030. Cytomegalovirus (CMV) treatment involves various approaches depending on the severity of the infection, the specific population affected, and the clinical manifestations. CMV is a type of herpesvirus that can cause infections in people with weakened immune systems, such as transplant recipients, individuals with HIV/AIDS, and newborns. The expansion of the CMV treatment market is fueled by the growing incidence of CMV infection and advancements in the development of increasingly efficacious treatments. Common treatment modalities encompass antiviral medications, immunoglobulin therapy, and stem cell transplantation. Market growth is propelled by the rising prevalence of chronic diseases, an escalating demand for personalized medicine, and the enhanced accessibility of CMV treatments in developing nations. Also, the Cytomegalovirus Treatment (CMV) Market is expanding because of factors such as the rising awareness and introduction of new drug therapies, increase in the patient pool of CMV retinitis and congenital CMV infection, coupled with the growing support from government bodies and funding for research and development initiatives.

In addition, the high prevalence of infectious diseases among AIDS patients are acting as a catalyzing factor for market growth across the globe. According to the WHO updates from November 2022, an estimated 38.4 million people were living with HIV, with 36.7 million adults and 1.7 million children affected with HIV in 2021. Cytomegalovirus (CMV) is accounted as one of the most prevalent Opportunistic Infections (OIs) documented in individuals with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), accordingly the demand for cytomegalovirus treatment is expected to rise over the forecast period. Thus, these aforementioned factors are propelling the growth of the Cytomegalovirus Treatment (CMV) Market over the estimated period. Moreover, the increasing technological advancements in treatment approaches, as well as the rising product approvals and product developments by various key market players present various lucrative opportunities over the forecast years. However, the adverse effects and risks related to cytomegalovirus drugs, along with the high cost associated with the treatment are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Cytomegalovirus Treatment (CMV) Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the growing consumer awareness, increasing immunosuppressed patient population, and the substantial presence of key market players. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increasing incidences of CMV infections, increasing government initiatives and funding, rising geriatric population, as well as improved awareness about CMV infections and advancements in diagnostic technologies are significantly propelling the market demand across the region.

Major market players included in this report are:
Clinigen Group PLC
F. Hoffmann-La Roche Ltd
Fresenius Kabi AG
Genentech Inc
Merck & Co. Inc
Mylan N.V.
Teva Pharmaceuticals Inc
Thermo Fisher Scientific Inc
Takeda Pharmaceuticals Company Limited
Pfizer Inc.

Recent Developments in the Market:
 In September 2022, ProBioGen and the City of Hope revealed a formalized commercial license agreement, enabling the utilization of the advanced AGE1.CR.pIX vaccine manufacturing platform for the development of the Cytomegalovirus (CMV) vaccine.
 In June 2022, Synklino successfully concluded a Series A fundraising round, securing a total of EUR 29.8 million (USD 31.8 million) in capital. The organization is dedicated to the development of pharmaceuticals aimed at addressing chronic viral infections, with a particular focus on advancing its drug candidate, SYN002, designed for the treatment of cytomegalovirus (CMV). The acquired funds will be strategically allocated towards advancing the development of SYN002.

Global Cytomegalovirus Treatment (CMV) Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Application, Distribution Channel, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Application:
Stem Cell Transplantation
Organ Transplantation
Congenital CMV Infection
Other Applications

By Distribution Channel:
Hospital pharmacies
Retail Pharmacies
E-commerce

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Clinigen Group PLC
F. Hoffmann-La Roche Ltd
Fresenius Kabi AG
Genentech Inc
Merck & Co. Inc
Mylan N.V.
Teva Pharmaceuticals Inc
Thermo Fisher Scientific Inc
Takeda Pharmaceuticals Company Limited
Pfizer Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.